| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000045111 |
| Receipt No. | R000051379 |
| Scientific Title | The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial. |
| Date of disclosure of the study information | 2021/08/10 |
| Last modified on | 2021/08/10 (Ver. 1) |
| Basic information | ||
| Public title | The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
|
|
| Acronym | The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial. | |
| Scientific Title | The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial. | |
| Scientific Title:Acronym | The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial. | |
| Region |
|
|
| Condition | ||
| Condition | esophageal cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | We investigated the possibility that continuous intravenous fentanyl and IV acetaminophen with transversus abdominis plane block could replace epidural anesthesia in thoracoscopic esophageal surgery. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Numerical Rating Scale (NRS) at postoperative day 1 and 3 and 5. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Epi group : The epidural catheter is inserted between the 8th and 9th vertebrae. 100 ml of 0.25% levobupivacaine, 20 ml of fentanyl, and 80 ml of saline are infused continuously at 2-6 ml/hr. After completion of the medication, 100 ml of 0.25% levobupivacaine and 100 ml of saline are added and continued until the 5POD. | |
| Interventions/Control_2 | TAP+FA group : Intraoperative transversus abdominis plane block is performed with 40 ml of 0.5% levobupivacaine. Fentanyl IV-PCA (0.025mg/ml, lockout time 10 min) and IV acetaminophen 1000 mg every 6 hours are administered immediately before the end of surgery and continued until the 5POD. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients with esophageal cancer who are hospitalized or attending the Department of Gastroenterology and General Surgery, Showa University Hospital, and who have undergone radical thoracoscopic subtotal esophagectomy
2) Patients whose age at the time of consent acquisition is between 20 and 75 years old. 3) Patients who have given written consent to participate in this study. |
|||
| Key exclusion criteria | (1) Patients with contraindications to the administration of levobupivacaine, fentanyl, or acetaminophen.
(2) Patients who are at risk for epidural anesthesia catheter insertion or who have difficulty in insertion. (3) Patients who have difficulty in interviewing for postoperative pain assessment (dementia, postoperative intubation status, etc.). (4) Patients with serious hepatic, renal, or cardiac disorders that may affect the safety assessment of the drug. 5) Patients with additional painful procedures such as insertion of additional thoracic drains in the postoperative course, or with postoperative complications that affect postoperative pain. (6) Patients who have been administered anticoagulants before surgery. (7) Patients deemed ineligible by the research physician. |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | SHOWA University | ||||||
| Division name | General and Gastroenterological Surgery | ||||||
| Zip code | 1428555 | ||||||
| Address | 1-5-8 Hatanodai, Shinagawa, Tokyo | ||||||
| TEL | 0337848541 | ||||||
| tariyoshi@med.showa-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | SHOWA University | ||||||
| Division name | General and Gastroenterological Surgery | ||||||
| Zip code | 1428555 | ||||||
| Address | 1-5-8 Hatanodai, Shinagawa, Tokyo | ||||||
| TEL | 0337848541 | ||||||
| Homepage URL | |||||||
| tariyoshi@med.showa-u.ac.jp | |||||||
| Sponsor | |
| Institute | SHOWA University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | SHOWA University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Showa University Medical Ethics Organization |
| Address | 1-5-8 Hatanodai, Shinagawa, Tokyo |
| Tel | 0337848129 |
| m-rinri@ofc.showa-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051379 |